Mark Paris

Mark Paris is an accomplished professional in the field of oncology and biopharmaceuticals, currently serving as Executive Director of Oncology Search and Evaluation at Daiichi Sankyo, Inc. since November 2019, having previously held the position of Senior Director in the same area. Before joining Daiichi Sankyo, Mark was with Mitra Biotech from December 2016 to November 2019, where responsibilities included expanding awareness of CANscript capabilities and engaging clients while holding positions such as Director and Associate Director of Translational Applications. Earlier in the career, Mark contributed to Clearpoint Strategy Group as a Senior Analyst, providing competitive intelligence solutions to biopharma clients. Mark's experience at Vaccinex Inc. spanned from 2001 to July 2016, where significant roles included Director of Bioinformatics and Molecular Biology, leading various studies and managing the Molecular Biology Core. As a co-founder of GeneBot LLC, Mark played a key role in developing innovative medical information solutions. Mark Paris earned a Ph.D. in Genetics from Case Western Reserve University School of Medicine between 1995 and 2000.